Promising two new drugs can be a treatment for chronic back pain.

Millions of people around the world are suffering from chronic low back pain, often looking for relief through temporary solutions such as painkillers and invasive surgery. But groundbreaking research McGill University It provides new hope. Scientists have confirmed two promising drugs dealing with the root cause. Cell cells also called “zombie cells”.

Aging cells are naturally accumulated due to damage from age or stress, such as DNA damage, oxidation stress or mitochondrial dysfunction. These cells refuse to die and instead release harmful substances jointly known as aging -related secretion (SASP).

SASP factors include inflammatory proteins, enzymes and reactive molecules, which damage healthy tissues and accelerate degenerative diseases, including heart disease, cancer, osteoarthritis and back pain.

Lisbet Haglund, the senior author and professor of MCGill’s surgery department, is interesting because our findings suggest that we can treat back pain in a completely new way.

In order to test their approach, the researchers performed experiments using genetically manipulated mice to cause symptoms similar to human spine degeneration. These mice lack the gene called sparc, causing initial spine worsening, inflammation and chronic pain.

The researchers have administered two drugs to this mouse, O-Vanillin: O-Vanillin, a former FDA approval drug, O-Vanillin, a natural compound extracted from turmeric. Both drugs reduced the pain, inflammation and degeneration of the spinal disc, but the combined use was much more powerful.

Haglund said, “We were surprised that oral treatment could reach the spinal disc, which emphasizes the interesting new possibilities that can effectively manage low back pain in the sauce, rather than simply solving the symptoms.

This drug belongs to a category known as Senollytics, especially aging cells, and remove aging cells. RG-7112 acts by inhibiting proteins involved in cell survival, allowing the body to remove these harmful cells more easily. On the other hand, O-vanilin has been almost accidentally included due to known anti-inflammatory characteristics and surprisingly proved to be able to remove aging cells.

The researchers also improved quality in the spinal bones and observed that the expression of pain markers in the spinal cord has greatly reduced. This comprehensive improvement emphasizes the potential of the drug as a deformation therapy for chronic pain.

Low back pain remains a major cause of disability worldwide, and in the United States alone, it has personal pain and economic burden, exceeding $ 100 billion every year. Treatment that deals with the root cause rather than symptoms can dramatically change how chronic pain is managed.

This study is especially promising because it not only worsens regression by releasing harmful substances, but also causes aging in adjacent healthy cells to produce damaged cascades. Early removing this cell can interfere with this destructive cycle.

Previous studies have proven to have reduced cell accumulation and spinal degeneration of genetic deletion of certain markers associated with aging, such as protein P16ink4a. This evidence uses Senollytics such as RG-7112 and O-Vanillin to strengthen the strategy to prevent or reverse damage.

Such findings are promising, but further studies are needed to identify the effects and safety of these drugs. Haglund and her team are chemically modifying O-vanilin, more stable and effective over the long term of the body. Potential applications can be helpful for patients suffering from other age -related diseases beyond arthritis, osteoporosis and aging.

Haglund said, “The big problem now is whether these drugs can have the same effect on humans. If we succeed, this study can open a way for the treatment of new kinds that improve the quality of life by directly targeting cell aging and degeneration.

Open Science development And Matthew Mannarino, Hosni Cherif, Lisbet Haglund, and Coworkers’ written by colleagues provide detailed scientific evidence that supports the use of segmented drugs for chronic low back pain.

In the preclinical test, the mouse showed the reduction of pain behavior, the improvement of spinal health and the reduction of inflammatory markers after 8 weeks of treatment. This suggests a promising new path for millions of people dealing with chronic pain.

This development reflects the transition to a targeted biological -based treatment that promises more effective and persistent mitigation than the current symptom approach. Continuous research allows treatments using RG-7112 and O-Vanillin to change the lives of people suffering from chronic low back pain and other painful degenerative conditions.